Literature DB >> 17898052

A high viral burden predicts the loss of CD8 T-cell responses specific for subdominant gag epitopes during chronic human immunodeficiency virus infection.

Christof Geldmacher1, Clive Gray, Martha Nason, Jeffrey R Currier, Antelmo Haule, Lilian Njovu, Steffen Geis, Oliver Hoffmann, Leonard Maboko, Andreas Meyerhans, Josephine Cox, Michael Hoelscher.   

Abstract

Human immunodeficiency virus (HIV)-specific CD8 T-cell responses targeting products encoded within the Gag open reading frame have frequently been associated with better viral control and disease outcome during the chronic phase of HIV infection. To further clarify this relationship, we have studied the dynamics of Gag-specific CD8 T-cell responses in relation to plasma viral load and time since infection in 33 chronically infected subjects over a 9-month period. High baseline viral loads were associated with a net loss of breadth (P < 0.001) and a decrease in the total magnitude of the Gag-specific T-cell response in general (P = 0.03). Most importantly, the baseline viral load predicted the subsequent change in the breadth of Gag recognition over time (P < 0.0001, r(2) = 0.41). Compared to maintained responses, lost responses were low in magnitude (P < 0.0001) and subdominant in the hierarchy of Gag-specific responses. The present study indicates that chronic exposure of the human immune system to high levels of HIV viremia is a determinant of virus-specific CD8 T-cell loss.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17898052      PMCID: PMC2168820          DOI: 10.1128/JVI.01566-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

Authors:  M Dalod; M Dupuis; J C Deschemin; C Goujard; C Deveau; L Meyer; N Ngo; C Rouzioux; J G Guillet; J F Delfraissy; M Sinet; A Venet
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection.

Authors:  M R Betts; D R Ambrozak; D C Douek; S Bonhoeffer; J M Brenchley; J P Casazza; R A Koup; L J Picker
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection.

Authors:  David H O'Connor; Todd M Allen; Thorsten U Vogel; Peicheng Jing; Ivan P DeSouza; Elizabeth Dodds; Edward J Dunphy; Cheri Melsaether; Bianca Mothé; Hiroshi Yamamoto; Helen Horton; Nancy Wilson; Austin L Hughes; David I Watkins
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

4.  A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays.

Authors:  Jeffrey R Currier; Ellen G Kuta; Ellen Turk; Lyndsay B Earhart; Larry Loomis-Price; Sylvia Janetzki; Guido Ferrari; Deborah L Birx; Josephine H Cox
Journal:  J Immunol Methods       Date:  2002-02-01       Impact factor: 2.303

Review 5.  The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes.

Authors:  Tumelo Mashishi; Clive M Gray
Journal:  Clin Chem Lab Med       Date:  2002-09       Impact factor: 3.694

6.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles.

Authors:  Hendrik Streeck; Mathias Lichterfeld; Galit Alter; Angela Meier; Nickolas Teigen; Bader Yassine-Diab; Harlyn K Sidhu; Susan Little; Anthony Kelleher; Jean-Pierre Routy; Eric S Rosenberg; Rafick-Pierre Sekaly; Bruce D Walker; Marcus Altfeld
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

8.  Baseline survey of sexually transmitted infections in a cohort of female bar workers in Mbeya Region, Tanzania.

Authors:  G Riedner; M Rusizoka; O Hoffmann; F Nichombe; E Lyamuya; D Mmbando; L Maboko; P Hay; J Todd; R Hayes; M Hoelscher; H Grosskurth
Journal:  Sex Transm Infect       Date:  2003-10       Impact factor: 3.519

9.  Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.

Authors:  M M Addo; X G Yu; A Rathod; D Cohen; R L Eldridge; D Strick; M N Johnston; C Corcoran; A G Wurcel; C A Fitzpatrick; M E Feeney; W R Rodriguez; N Basgoz; R Draenert; David R Stone; C Brander; P J R Goulder; E S Rosenberg; M Altfeld; B D Walker
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.

Authors:  M Altfeld; E S Rosenberg; R Shankarappa; J S Mukherjee; F M Hecht; R L Eldridge; M M Addo; S H Poon; M N Phillips; G K Robbins; P E Sax; S Boswell; J O Kahn; C Brander; P J Goulder; J A Levy; J I Mullins; B D Walker
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

View more
  8 in total

1.  Fluidity of HIV-1-specific T-cell responses during acute and early subtype C HIV-1 infection and associations with early disease progression.

Authors:  Mandla Mlotshwa; Catherine Riou; Denis Chopera; Debra de Assis Rosa; Roman Ntale; Florette Treunicht; Zenda Woodman; Lise Werner; Francois van Loggerenberg; Koleka Mlisana; Salim Abdool Karim; Carolyn Williamson; Clive M Gray
Journal:  J Virol       Date:  2010-09-08       Impact factor: 5.103

2.  Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point.

Authors:  Clive M Gray; Mandla Mlotshwa; Catherine Riou; Tiyani Mathebula; Debra de Assis Rosa; Tumelo Mashishi; Cathal Seoighe; Nobubelo Ngandu; Francois van Loggerenberg; Lynn Morris; Koleka Mlisana; Carolyn Williamson; Salim Abdool Karim
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

3.  Relationship between chemokine receptor expression, chemokine levels and HIV-1 replication in the lungs of persons exposed to Mycobacterium tuberculosis.

Authors:  Barbara Kalsdorf; Keira H Skolimowska; Thomas J Scriba; Rod Dawson; Keertan Dheda; Kathryn Wood; Jessica Hofmeister; Willem A Hanekom; Christoph Lange; Robert J Wilkinson
Journal:  Eur J Immunol       Date:  2012-12-13       Impact factor: 5.532

4.  Defining Kinetic Properties of HIV-Specific CD8⁺ T-Cell Responses in Acute Infection.

Authors:  Yiding Yang; Vitaly V Ganusov
Journal:  Microorganisms       Date:  2019-03-04

5.  Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses.

Authors:  Ellen Van Gulck; Nathalie Cools; Derek Atkinson; Lotte Bracke; Katleen Vereecken; Marc Vekemans; Viggo F I Van Tendeloo; Zwi N Berneman; Guido Vanham
Journal:  Clin Dev Immunol       Date:  2012-07-12

6.  Crippling HIV one mutation at a time.

Authors:  Todd M Allen; Marcus Altfeld
Journal:  J Exp Med       Date:  2008-05-05       Impact factor: 14.307

7.  Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status.

Authors:  J William Critchfield; Delandy H Young; Timothy L Hayes; Jerome V Braun; Juan C Garcia; Richard B Pollard; Barbara L Shacklett
Journal:  PLoS One       Date:  2008-10-30       Impact factor: 3.240

8.  Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection.

Authors:  Paul Munson; Yi Liu; Debra Bratt; James T Fuller; Xintao Hu; George N Pavlakis; Barbara K Felber; James I Mullins; Deborah Heydenburg Fuller
Journal:  Hum Vaccin Immunother       Date:  2018-04-12       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.